Menopur vs Follistim: Key Differences in IVF Stimulation Medications 

By CNY Fertility Published on — Medically Reviewed and Certified by Lauren Miller, FNP-C Lauren Miller, FNP-C
Menopur vs Follistim: Key Differences in IVF Stimulation Medications 

Quick answer: Menopur vs Follistim

Menopur and Follistim are both effective IVF stimulation medications 

Menopur provides follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity, while Follistim provides recombinant FSH only. Neither medication is universally better. 

IVF outcomes depend on patient age, ovarian response, monitoring, and protocol design rather than medication brand. 

 

Menopur and Follistim are commonly used during IVF to stimulate the ovaries to produce multiple eggs in a single cycle. By increasing the number of eggs available for retrieval, both medications improve the chances of fertilization, embryo development, and pregnancy. 

While both medications support the same overall goal, they differ in hormonal composition and how they are used in IVF protocols. The choice between Menopur and Follistim is individualized and based on patient physiology, prior treatment response, and clinical strategy. 

This article explains how Menopur and Follistim compare, how doctors decide between them, what the research shows, and which patients may benefit from each approach. 

Menopur vs Follistim: Side-by-Side Comparison 

Feature 

Menopur 

Follistim 

Hormonal activity 

FSH + LH 

FSH only 

Medication type 

Human menopausal gonadotropin (hMG) 

Recombinant FSH 

Source 

Purified urinary-derived 

Laboratory-produced 

LH activity included 

Yes 

No 

Primary role in IVF 

 Develop multiple mature eggs 

 Develop multiple mature eggs 

Typical use 

When LH support is desired 

 When FSH-only stimulation is sufficient or LH is provided elsewhere 

 

Can be combined with other meds 

Yes 

Yes 

Advertisement – Making Genes come True

Why Ovarian Stimulation Medications Matter in IVF 

In a natural menstrual cycle, the body typically matures only one egg. IVF is effective in large part because ovarian stimulation medications override this limitation, allowing multiple follicles to grow and mature simultaneously. 

This ability to safely and predictably recruit multiple eggs is one of the primary drivers of IVF success, as it increases the number of eggs available for fertilization, embryo development, and selection. 

Strong FSH activity is central to this process. FSH stimulates granulosa cells within ovarian follicles and supports egg maturation. Both Menopur and Follistim deliver this critical signal, but they do so in different ways. 

What Is Follistim? 

Follistim AQ (follitropin beta injection) is a recombinant human FSH medication. It contains FSH only and does not provide LH activity. 

In IVF, Follistim is used during controlled ovarian stimulation to provide consistent FSH signaling, allowing multiple follicles to continue developing instead of regressing to a single dominant follicle. 

Key characteristics of Follistim: 

  • Recombinant (laboratory-produced) FSH 
  • Highly consistent dosing 
  • No intrinsic LH activity 
  • Often delivered via a pen device for precise dose adjustment 

What Is Menopur? 

Menopur (menotropins for injection) is a human menopausal gonadotropin (hMG) derived from purified urine of postmenopausal women. Each vial contains 75 IU of FSH activity and 75 IU of LH activity. 

Menopur is FDA-approved for ovarian stimulation in IVF and provides both FSH and LH activity in a single medication. 

The Core Difference: FSH-Only vs FSH + LH 

Follistim: FSH-Only Stimulation 

Follistim delivers sustained FSH signaling to promote follicle growth and increase the number of eggs available for retrieval. It does not directly provide LH activity during stimulation. 

Menopur: Combined FSH and LH Activity 

Menopur provides FSH to stimulate follicle growth and LH activity to support hormone production within the follicle. For some patients, LH activity may better mirror natural ovarian physiology. 

Is Menopur or Follistim Better for IVF? 

Neither Menopur nor Follistim is universally better for IVF. 

Clinical evidence shows that IVF success depends more on a patient’s age and medical profile, ovarian response, monitoring, and protocol design than on which stimulation medication is used.

Some studies and clinical experience suggest that Menopur may be beneficial for certain patient populations. However, this benefit is not universal, and Menopur should not be assumed to improve egg quality by default.

In general: 

  • Menopur may be preferred when added LH activity is expected to support follicular development
  • Follistimis is often sufficient when FSH-only stimulation produces an adequate response
  • LH activity, when needed, can also be provided through other approaches, such aslow-dose hCG, rather than relying on Menopur alone

Rather than choosing a “better” medication, fertility specialists select or combine medications to match the patient’s biology and treatment goals. 

These clinical patterns are supported by large studies and meta-analyses comparing human menopausal gonadotropins (hMG) with recombinant FSH.

At the population level, research shows no consistent difference in pregnancy or live birth rates when stimulation protocols are appropriately designed and monitored. Outcomes are driven primarily by individual ovarian response rather than medication brand. 

Can Menopur and Follistim Be Used Together? 

Yes. Many IVF protocols combine Menopur and Follistim to fine-tune the balance of FSH and LH activity. 

Common strategies include: 

  • Follistim as the primary FSH driver 
  • Menopur added to introduce LH activity 
  • Adjusting ratios based on real-time ovarian response 

This allows stimulation to be individualized rather than relying on a single medication approach. 

Follistim + Low-dose hCG (a Menopur Alternative) 

In some IVF protocols, Follistim is paired with low-dose hCG to provide LH-like activity rather than using Menopur. Because hCG activates the same LH receptor, it can supply functional LH support during stimulation. While hCG is not identical to LH, it provides similar biological activity at the ovarian level and is widely used in IVF protocols. 

This approach is commonly used for patients who require LH activity but are seeking a more cost-effective option, particularly those without insurance coverage for Menopur or with high out-of-pocket medication costs. 

As with all stimulation strategies, the decision to use Menopur or low-dose hCG depends on ovarian response, hormone levels, and clinical goals, not cost alone. 

Side Effects of Menopur and Follistim 

Menopur and Follistim have similar side effect profiles because both medications stimulate the ovaries in comparable ways. Most side effects are related to ovarian stimulation itself rather than the specific medication used. 

Common side effects may include: 

  • Injection site discomfort, redness, or bruising 
  • Abdominal bloating or pelvic pressure 
  • Breast tenderness 
  • Headache or fatigue 
  • Mood changes related to hormone fluctuations 

Less common but more serious risks include: 

  • Ovarian hyperstimulation syndrome (OHSS) 
  • Ovarian enlargement or cyst formation 
  • Development of multiple follicles, which may increase the risk of multiple pregnancy if more than one embryo is transferred 

The risk of side effects depends primarily on individual ovarian response, medication dosing, and monitoring, not on whether Menopur or Follistim is used. Careful ultrasound and hormone monitoring during stimulation allows fertility specialists to adjust dosing and reduce risk. 

Limitations of Both Medications 

Menopur and Follistim: 

  • Cannot reverse age-related fertility decline 
  • Do not guarantee embryo development or pregnancy 
  • Are only one component of IVF success 

Egg quality is primarily influenced by age and genetics. 

Cost Differences Between Menopur and Follistim 

Medication costs are one of the largest variables in the total cost of an IVF cycle. While pricing can vary by pharmacy, dosage, and insurance coverage, Menopur is typically more expensive than Follistim on a per-unit basis. 

In many standard stimulation protocols: 

  • IVF cycles using Follistim often result in medication costs of roughly $3,000 on average, though totals can certainly be higher or lower depending on dosage and cycle length. 
  • Protocols that rely heavily on Menopur often average around $4,500 or more in medication costs, again depending on how much Menopur is used during stimulation. 
  • In some protocols, Follistim may be paired with low-dose hCG instead of Menopur, which can reduce medication costs for some patients while still providing LH-like activity during stimulation. 
  • Medication costs ultimately depend on the total dose required, not just the medication name. A low-dose protocol using Menopur could cost less than a higher-dose protocol using Follistim. 

Because stimulation medications are individualized, the most accurate estimate of medication cost usually comes after a treatment protocol is designed and dosing is determined. 

Menopur vs Follistim: Key Takeaways 

  • Menopur and Follistim are both effective IVF stimulation medications 
  • Follistim provides FSH only; Menopur provides FSH plus LH activity 
  • IVF outcomes are comparable at the population level 
  • Some patients benefit from LH activity, while others do not 
  • Medications are often combined to individualize stimulation 
  • Protocol design and monitoring matter more than brand 

 

Article Sources